214 related articles for article (PubMed ID: 36232554)
1. Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma.
Gesmundo I; Pedrolli F; Vitale N; Bertoldo A; Orlando G; Banfi D; Granato G; Kasarla R; Balzola F; Deaglio S; Cai R; Sha W; Papotti M; Ghigo E; Schally AV; Granata R
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232554
[TBL] [Abstract][Full Text] [Related]
2. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
4. Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity.
Pinton G; Manente AG; Daga A; Cilli M; Rinaldi M; Nilsson S; Moro L
Mol Cancer; 2014 Oct; 13():227. PubMed ID: 25277603
[TBL] [Abstract][Full Text] [Related]
5. Schedule-Dependent Treatment Increases Chemotherapy Efficacy in Malignant Pleural Mesothelioma.
Karatkevich D; Deng H; Gao Y; Flint E; Peng RW; Schmid RA; Dorn P; Marti TM
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233258
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F
Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332
[TBL] [Abstract][Full Text] [Related]
7. SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.
Iwahori K; Serada S; Fujimoto M; Ripley B; Nomura S; Mizuguchi H; Shimada K; Takahashi T; Kawase I; Kishimoto T; Naka T
Int J Cancer; 2013 Jan; 132(2):459-71. PubMed ID: 22532243
[TBL] [Abstract][Full Text] [Related]
8. 2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth.
Gerogianni I; Pitaraki E; Jagirdar RM; Kouliou O; Giannakou L; Giannopoulos S; Papazoglou E; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
Anticancer Res; 2019 Jul; 39(7):3809-3814. PubMed ID: 31262908
[TBL] [Abstract][Full Text] [Related]
9. Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts.
Lam SK; Li YY; Xu S; Leung LL; U KP; Zheng YF; Cheng PN; Ho JC
Respir Res; 2017 May; 18(1):80. PubMed ID: 28464918
[TBL] [Abstract][Full Text] [Related]
10. The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
Li Q; Yano S; Ogino H; Wang W; Uehara H; Nishioka Y; Sone S
Clin Cancer Res; 2007 Oct; 13(19):5918-25. PubMed ID: 17908988
[TBL] [Abstract][Full Text] [Related]
11. Combined hyaluronate-based films loaded with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma: Preliminary evaluation in an orthotopic tumor recurrence model.
Sonvico F; Barbieri S; Colombo P; Barocelli E; Mucchino C; Cantoni AM; Petronini PG; Rusca M; Carbognani P; Ampollini L
Eur J Pharm Sci; 2018 Oct; 123():89-97. PubMed ID: 30030099
[TBL] [Abstract][Full Text] [Related]
12. Combination effect of photodynamic therapy using NPe6 with pemetrexed for human malignant pleural mesothelioma cells.
Maehara S; Usuda J; Ishizumi T; Ichinose S; Ohtani K; Inoue T; Imai K; Furumoto H; Kudo Y; Kajiwara N; Ohira T; Ikeda N
Int J Oncol; 2015 Feb; 46(2):741-9. PubMed ID: 25385189
[TBL] [Abstract][Full Text] [Related]
13. Butein impairs the protumorigenic activity of malignant pleural mesothelioma cells.
Cioce M; Canino C; Pulito C; Muti P; Strano S; Blandino G
Cell Cycle; 2012 Jan; 11(1):132-40. PubMed ID: 22185775
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone-releasing hormone antagonist MIA-602 inhibits inflammation induced by SARS-CoV-2 spike protein and bacterial lipopolysaccharide synergism in macrophages and human peripheral blood mononuclear cells.
Granato G; Gesmundo I; Pedrolli F; Kasarla R; Begani L; Banfi D; Bruno S; Lopatina T; Brizzi MF; Cai R; Sha W; Ghigo E; Schally AV; Granata R
Front Immunol; 2023; 14():1231363. PubMed ID: 37649486
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
Hassan R; Sharon E; Thomas A; Zhang J; Ling A; Miettinen M; Kreitman RJ; Steinberg SM; Hollevoet K; Pastan I
Cancer; 2014 Nov; 120(21):3311-9. PubMed ID: 24989332
[TBL] [Abstract][Full Text] [Related]
16. A Case Report of Primary Pericardial Malignant Mesothelioma Treated with Pemetrexed and Cisplatin.
Kim JS; Lim SY; Hwang J; Kang EJ; Choi YJ
J Korean Med Sci; 2017 Nov; 32(11):1879-1884. PubMed ID: 28960045
[TBL] [Abstract][Full Text] [Related]
17. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
Tsao AS; Miao J; Wistuba II; Vogelzang NJ; Heymach JV; Fossella FV; Lu C; Velasco MR; Box-Noriega B; Hueftle JG; Gadgeel S; Redman MW; Gandara DR; Kelly K
J Clin Oncol; 2019 Oct; 37(28):2537-2547. PubMed ID: 31386610
[TBL] [Abstract][Full Text] [Related]
18. A molecular targeting against nuclear factor-κB, as a chemotherapeutic approach for human malignant mesothelioma.
Nishikawa S; Tanaka A; Matsuda A; Oida K; Jang H; Jung K; Amagai Y; Ahn G; Okamoto N; Ishizaka S; Matsuda H
Cancer Med; 2014 Apr; 3(2):416-25. PubMed ID: 24510578
[TBL] [Abstract][Full Text] [Related]
19. Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.
Takeda T; Itano H; Fukita S; Saitoh M; Takeda S
Intern Med; 2014; 53(20):2347-51. PubMed ID: 25318801
[TBL] [Abstract][Full Text] [Related]
20. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]